Physician profile

Daniel Wise

Cardiovascular Disease · Charlotte, NC

NPI 1780625319

$24,205.30

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$23.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

Show all 25 companies
CompanyGeneral paymentsYearsTop products
Arbor Pharmaceuticals, INC. $35.63 2019
Merck Sharp & Dohme LLC $29.10 2019
W. L. Gore & Associates, INC. $23.38 2023 Viatorr Tips Endoprosthesis W/ Controlled Expansion
Pfizer INC. $21.60 2019
Aegerion Pharmaceuticals, INC. $17.09 2019
Gilead Sciences, INC. $16.89 2019
Eisai INC. $14.74 2019
Amneal Pharmaceuticals LLC $13.70 2019
Vivus LLC $13.22 2019
E.R. Squibb & Sons, L.L.C. $11.12 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Wise

$24,205.30

in general payments reported 2019-2025

Years
2019-2023
Top company
Amgen INC.

https://glasscript.com/doctor/35915/daniel-wise

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.